Agenda & Faculty, July 11-14 2024

13:00

Registration Opens

13:50

Opening remarks – Ryan Fitzpatrick, CEO, MD Education

Session I

Moderators: Elias Jabbour, MD

14:00

CLL Highlights

William Wierda, MD MD Anderson Cancer Center, Houston, Texas

14:20

MDS Highlights

Rami Komrokji, MD Moffit Cancer Center, Florida

14:40

Panel Discussion

15:00

Coffee Break & Networking

15:20

Industry supported independent expert discussion

Session II

Moderators: Naval Daver, MD and Eunice Wang, MD

16:05

BPDCN Highlights

Naveen Pemmaraju, MD MD Anderson Cancer Center, Houston, Texas

16:25

Pediatric Leukemia Highlights

Branko Cuglievan, MD MD Anderson Cancer Center, Houston, Texas

16:45

CML Highlights

Hagop Kantarjian, MD MD Anderson Cancer Center, Houston, Texas

17:05

Panel Discussion

17:25

Adjourn

07:30am

Registration opens

Session III

Moderators: Charlie Craddock, MD and Courtney DiNardo, MD

08:10

Current and Future Research Directions in AML

Hagop Kantarjian MD MD Anderson Cancer Center, Houston, Texas

08:30

The Genetic landscape and molecular diagnostics in AML

Joseph D. Khoury, MD University of Nebraska, Nebraska

08:50

Optimizing frontline therapy for FLT3 mutated AML patients eligible for intensive

Harry P. Erba, MD Duke University, North Carolina

09:10

Genomic strategies to guide the choice of invasive treatment strategies in non-FLT3m AML

Amir Fathi, MD Massachusetts General Hospital, Massachusetts

09:30

Diagnostic and molecular work-up of newly diagnosed AML – The pathologists perspective

Sanam Loghavi, MD MD Anderson Cancer Center, Houston, Texas

09:50

Panel Discussion

10:10

Coffee Break & Networking

Session IV

Moderators: Ibrahim Aldoss, MD and Anjali Advani, MD

10:30

Molecular Biology

Charles Mullighan, MD St. Jude Children’s Research Hospital, Memphis, Tennessee

10:50

Philadelphia +ive ALL

Elias Jabbour, MD MD Anderson Cancer Center, Houston, Texas

11:10

Ph- ALL MRD –

Aaron Logan, MD UCSF Helen Diller Family Comprehensive Cancer Center, California

11:30

New Targets in ALL

Cristina Papayannidis, MD Austin Diagnostic Clinic, TX

11:50

Panel Discussion

12:10

Lunch Break & Group Photo

13:00

Industry supported independent expert discussion

Session V

Moderators: Naval Daver, MD and Eunice Wang, MD

13:45

Updates on the management and mechenisms of resistance in R/R FLT3m AML

Alexander Perl, MD Perelman School of Medicine, Pennsylvania

14:05

Emerging strategies to improve outcome of allo-transplant in AML

Charlie Craddock, MD Queen Elizabeth Hospital, Birmingham

14:25

How do I assess for MRD in clinical practice and how do I use MRD to guide post remission therapy

Farhad Ravandi, MD MD Anderson Cancer Center, Houston, Texas

14:45

How do I use IDH inhibitors in frontline and R/R setting: Single agent versus combinations

Courtney DiNardo, MD MD Anderson Cancer Center, Houston, Texas

15:05

Current status and future directions with menin inhibitors in AML

Eytan Stein, MD Memorial Sloan Kettering Cancer Center, New York City, New York.

15:25

Panel Discussion

15:45

Coffee Break & Networking

Session VI

Moderators: Bijal Shah, MD and Nitin Jain, MD

16:05

Integration of immune-therapy into frontline ALL – HCVAD experience

Elias Jabbour, MD MD Anderson Cancer Center, Houston, Texas

16:25

Integration of immune-therapy into frontline ALL – Regimens

Mark Litzow, MD Mayo Clinic, Florida

16:45

AYA ALL

Wendy Stock, MD The University of Chicago Medicine, Illinois

17:05

Transplant in ALL

Ibrahim Aldoss, MD City of Hope Comprehensive Cancer Center, California

17:25

Panel Discussion

17:45

Adjourn

08:00

Registration Opens

Session VII

Moderators: Tapan Kadia, MD and Eytan Stein, MD

Debate: Upfront triplets vs sequential therapies for the treatment of AML

09:00

The case for sequential therapies

Eunice Wang, MD Roswell Park Comprehensive Cancer Center, Buffalo, New York

09:10

The case for upfront triplets

Naval Daver, MD MD Anderson Cancer Center, Houston, Texas

09:20

Debate Discussion

09:30

Developing Immune and cellular therapies in AML

Yasmin Abaza, MD Northwestern University Feinberg School of Medicine, Illinois

09:50

Panel Discussion

10:10

Coffee Break & Networking

Session VIII

Moderators: Aaron Logan, MD and Jae Park, MD

10:30

Older ALL

Anjali Advani, MD Cleveland Clinic, Ohio

10:50

BC2 Inhibitors in AML

Daniel J. DeAngelo, MD Dana-Farber Cancer Institute, Massachusetts

11:10

PH – lite ALL

Marina Konopleva, MD Albert Einstein College of Medicine, New York

11:30

New drugs in T-Cell

Nitin Jain, MD MD Anderson Cancer Center, Houston, Texas

11:50

Panel Discussion

12:10

Lunch & Networking

13:00

Industry supported independent expert discussion

Session IX

Moderators: Dan Pollyea, MD and Farhad Ravandi, MD

13:45

Mechanisms of resistance and novel combinations with ventoclax based therapies in AML

Marina Konopleva, MD Albert Einstein College of Medicine, New York

14:05

Optimizing maintenance therapy in AML post-consolidation and post-transplant

Tapan Kadia, MD MD Anderson Cancer Center, Houston, Texas

14:25

Immune based and other novel approaches to move the bar forward in the treatment of MDS

Hetty Carraway, MD Cleveland Clinic, Ohio

14:45

Optimizing SCT approaches including conditioning the maintenance in AML

Elizabeth J Shpall, MD MD Anderson Cancer Center, Houston, Texas

15:05

Panel Discussion

15:25

Coffee Break & Networking

Session X

Moderators: Wendy Stock, MD and Marina Konopleva, MD

15:45

CAR-T: Finite therapy

Jae Park, MD Memorial Sloan Kettering Cancer Center, New York City, New York.

16:05

CAR-T: Bridging for ASCT

Bijal Shah, MD Moffitt Cancer Center, Florida

16:25

Future of ALL

Hagop Kantarjian, MD MD Anderson Cancer Center, Houston, Texas

16:45

Panel Discussion

17:05

Adjourn